Transendothelial movement of adiponectin is restricted by glucocorticoids

Thanh Q Dang1,*, Nanyoung Yoon1,*, Helen Chasiotis1, Emily C Dunford2, Qilong Feng3, Pingnian He3, Michael C Riddell2, Scott P Kelly1 and Gary Sweeney1

1Department of Biology, Faculty of Science York University, Toronto, Canada
2School of Kinesiology and Health Science, Faculty of Health and Muscle Health Research Center, York University, Toronto, Canada
3Department of Cellular and Molecular Physiology, College of Medicine, Pennsylvania State University, Hershey, PA, USA
*(T Q Dang and N Yoon contributed equally to this work)

Abstract

Altered permeability of the endothelial barrier in a variety of tissues has implications both in disease pathogenesis and treatment. Glucocorticoids are potent mediators of endothelial permeability, and this forms the basis for their heavily prescribed use as medications to treat ocular disease. However, the effect of glucocorticoids on endothelial barriers elsewhere in the body is less well studied. Here, we investigated glucocorticoid-mediated changes in endothelial flux of Adiponectin (Ad), a hormone with a critical role in diabetes. First, we used monolayers of endothelial cells in vitro and found that the glucocorticoid dexamethasone increased transendothelial electrical resistance and reduced permeability of polyethylene glycol (PEG, molecular weight 4000 Da). Dexamethasone reduced flux of Ad from the apical to basolateral side, measured both by ELISA and Western blotting. We then examined a diabetic rat model induced by treatment with exogenous corticosterone, which was characterized by glucose intolerance and hyperinsulinemia. There was no change in circulating Ad but less Ad protein in skeletal muscle homogenates, despite slightly higher mRNA levels, in diabetic vs control muscles. Dexamethasone-induced changes in Ad flux across endothelial monolayers were associated with alterations in the abundance of select Claudin tight junction (TJ) proteins. shRNA-mediated knockdown of one such gene, claudin-7, in HUVEC resulted in decreased TEER and increased adiponectin flux, confirming the functional significance of Dex-induced changes in its expression. In conclusion, our study identifies glucocorticoid-mediated reductions in flux of Ad across endothelial monolayers in vivo and in vitro. This suggests that impaired Ad action in target tissues, as a consequence of reduced transendothelial flux, may contribute to the glucocorticoid-induced diabetic phenotype.
Introduction

As the primary barrier to the movement of circulating endocrine factors from the bloodstream to the interstitial space, the endothelium plays a critical role in hormone action (Kolka & Bergman 2012, Yoon et al. 2014). Endothelial permeability can significantly impact hormone action by preventing or delaying access of the hormone to target tissues (Won et al. 2011, Kolka & Bergman 2012). Transendothelial solute movement can occur via the transepithelial pathway where solutes are transported across the endothelium cell membrane or via the paracellular pathway where solutes passively move through the intercellular space between adjacent endothelial cells (Yoon et al. 2014). Previous work has shown that hormone and nutrient concentrations in blood differ from surrounding cells on the tissue side of the blood vessel endothelium (Yang et al. 1994, Herkner et al. 2003, Barrett et al. 2011). Of note, this has been best documented in the case of insulin where concentrations of the hormone are significantly lower in the target tissue than those in the circulation (Kolka & Bergman 2012).

Glucocorticoids are among the most commonly prescribed anti-inflammatory and immunosuppressive medications worldwide (Clark & Belvisi 2012). They are also commonly used in oncology treatment (Lin & Wang 2016) and for the treatment of macular edema and, more recently, retinopathy (Zhang et al. 2014, Agarwal et al. 2015). However, glucocorticoids have been shown to have potent effects on restricting endothelial transport (Felinski & Antonetti 2005, Witt & Sandoval 2014), and they contribute to the development of diabetes at least in part by increasing hepatic glucose production and reducing GLUT4 translocation in muscle (Beaudry et al. 2015). Yet despite these observations, the potential importance of glucocorticoid-induced alterations in the transendothelial flux of circulating glucoregulatory hormones such as Ad is unclear.

Ad is one of the most abundant plasma proteins and exists in three different isoforms: low molecular weight (LMW; trimer), medium molecular weight (MMW; hexamer) and high molecular weight (HMW; oligomer) (Dadson et al. 2011). Ad has important and beneficial anti-diabetic, anti-inflammatory and cardioprotective actions (Arita et al. 2002, Dadson et al. 2011). Ad levels, in particular HMW, are decreased in obese individuals, and this correlates with the development of associated complications, including diabetes and cardiovascular disease (Kadowaki et al. 2006, Peters et al. 2013). Transendothelial movement of Ad across the blood–brain barrier (BBB) into cerebrospinal fluid (CSF) was studied, and only LMW and MMW were found in the CSF, suggesting that passage of HMW complexes was restricted (Kubota et al. 2007, Kusminski et al. 2007, Neumeier et al. 2007). This may be functionally significant since HMW Ad is often considered to be the most biologically active and physiologically relevant form (Dadson et al. 2011, Nanayakkara et al. 2012). A recent study calculated the Stokes radii for the Ad oligomers and found that endothelial barriers controlled Ad transport in a cell- and tissue-specific manner (Rutkowski et al. 2014). Thus, emerging evidence suggests that Ad action may be at least in part mediated by endothelial transport, although whether this is influenced by glucocorticoid-induced changes in transendothelial permeability remains unknown.

Given the large size of Ad multimers, it seems likely that transendothelial Ad movement is an important variable in determining its presence within, and action on, target tissues. Therefore, we hypothesized that glucocorticoid-induced alterations in transendothelial permeability will modulate the transendothelial movement of Ad. In this regard, the objective of this study was to examine how glucocorticoid treatment of a cultured monolayer of endothelial cells influences Ad flux in association with changes in permeability and apical junction protein abundance as well as investigate Ad content within the skeletal muscle in a diabetic rat model induced by exogenous glucocorticoid treatment. The overall goal of this work was to significantly advance our understanding of the glucocorticoid-induced diabetic phenotype by determining whether Ad movement out of the circulatory system might play a role in its pathogenesis.

Materials and methods

HUVEC cell culture and treatments

Normal primary human umbilical vein endothelial cells (HUVECs; Pooled, PCS-100-013) were obtained from ATCC and grown at 37°C and 5% CO₂ on uncoated T75 flasks in vascular cell basal medium (ATCC, PCS-100-030) containing 10% fetal bovine serum (FBS), VEGF endothelial cell growth kit (ATCC, PCS-100-041) and treated with DEX using 2% FBS (both medium were prepared without hydrocortisone hemisuccinate), 100units/mL penicillin and 100µg/mL streptomycin. Cells were kept frozen in medium containing 10% DMSO
(Bio-Rad Laboratories Canada Ltd.). Forexperiments, passage 3 was used. Cells were counted using a hemocytometer and seeded onto permeable polyethylene terephthalate (PET) filters at the base of BD Falcon cell culture inserts (BD Biosciences, Mississauga, ON, Canada) at a density of 0.5 x 10^6 cells/insert.

Dexamethasone (DEX) was obtained from Sigma-Aldrich, and full-length Ad was produced in-house using a mammalian expression system (i.e. HEK 293 cells) according to methods described by Wang and coworkers (2002) and Xu and coworkers (2004). 24h after seeding into inserts, HUVECs were treated with Dex (1 µM), on both apical and basolateral side, for 5 days.

**shRNA-mediated knockdown of claudin-7 in HUVEC**

We used pGPU6/Neo-claudin-7 shRNA vector with target sequence (5′-GGCCATCAGATTGTCACAGAC-3′) (GenePharma Co., Ltd., Shanghai, China). These were transfected into HUVEC using Lipofectamine 3000 Reagent (Invitrogen) exactly according to manufacturer’s protocol. Non-specific scrambled target sequence shRNA vector was used as control. Following selection with 50 µg/mL Neomycin (Sigma-Aldrich) for 24 h, cells were seeded onto inserts for analysis of TEER, examining adiponectin flux or preparation of cell lysates to confirm claudin-7 knockdown.

**Transendothelial electrical resistance (TEER), and [3H]PEG-4000 and Ad flux**

TEER was measured daily using chopstick electrodes (STX-2) connected to an EVOM voltohmmeter (World Precision Instruments, Sarasota, FL, USA). As a measure of paracellular permeability, apical-to-basolateral flux rates of [3H] polyethylene glycol at 1 µCi; 1 h flux (molecular mass 4000 Da; PEG-4000; PerkinElmer) or Ad (10 µg/mL; 24 h flux) to apical culture medium were determined across HUVEC endothelia. [3H]PEG-4000 in basolateral culture medium was detected using a liquid scintillation counter, Ad was detected using a mouse Ad ELISA kit (Antibody Immunoassay Services, Hong Kong) or Western blot. Permeability measurements were expressed according to calculations previously outlined by Wood and coworkers (Wood et al. 1998).

**L6 and H9C2 cell culture and treatment with HUVEC-conditioned medium**

Rat myoblasts and cardiomyocytes at passage 22-30 were grown in α_AMEM (Life Technologies) and DMEM containing 10% FBS and 1% antibiotic–antimycotic (Wisent Inc., St-Bruno, QC, Canada). Culture media from the basolateral compartment of HUVEC inserts were collected and applied. L6/H9C2 cells were starved with medium containing 0.5% FBS and 1% antibiotic–antimycotic for 3h prior to treatment with HUVEC-conditioned medium.

**Quantitative real-time PCR analysis**

Total RNA was isolated from control and DEX-treated HUVECs and from soleus skeletal muscle using TRIzol Reagent. Extracted RNA was then treated with DNase I, and first-strand cDNA was synthesized using SuperScript III reverse transcriptase and oligo(dT)_{12-18} primers (Life Technologies). Quantitative real-time PCR (qRT-PCR) analyses were conducted using gene-specific primers. SYBR Green I Supermix (Bio-Rad Laboratories Canada Ltd.) and a Chromo4 Detection System (CFB-3240; Bio-Rad Laboratories Canada Ltd.) samples were run in duplicate. For all qRT-PCR analyses, TJ protein mRNA expression was normalized to GAPDH transcript abundance. For the expression profile, TJ protein transcripts were expressed relative to occludin mRNA. For TJ protein transcripts that were not detected in HUVECs, normal human adult kidney cDNA was obtained (BioChain Institute, Inc., Newark, CA, USA) and used as a positive control in qRT-PCR reactions. Agarose gel electrophoresis verified single qRT-PCR products at predicted amplicon sizes from positive control reactions.

**Animal model of diabetes induced by exogenous corticosterone treatment**

We used a well-established hyperinsulinemic/hyperglycemic rodent model of chronic glucocorticoid treatment (D’Souza et al. 2012, Shikatani et al. 2012, Shpilberg et al. 2012, Beaudry et al. 2013, 2015). Upon experiment cessation, the tibialis anterior (TA) and soleus skeletal muscles were excised and immediately frozen in liquid N₂ and kept at −80°C until future analysis.
Oral glucose tolerance test

Animals were fasted overnight (16 h), 11 days after pellet implantation, and were administered an oral glucose tolerance test (OGTT, 1.5 g/kg body mass) on day 12 using glucometer (Bayer One Touch); additional fasted plasma was collected for later analysis of insulin concentrations via an ELISA 96-well kit (Crystal Chem, USA). Plasma for measurement of Ad concentration was obtained 7 days after pellet implantation at 08:00 h and assessed using a mouse Ad ELISA kit (AIS, Hong Kong).

Measurement of hydraulic conductivity (Lp) in individually perfused rat mesenteric microvessel

Female Sprague–Dawley rats of 220–250 g (2–3 months old, Sage Laboratory Animal, PA, USA) were used for the experiments. All procedures and animal use were approved by the Animal Care and Use Committee at Pennsylvania State University. Inactin, hydrate (Sigma) was used for anesthesia and given subcutaneously at 170 mg/kg body weight.

Microvessel permeability was assessed by measuring Lp in individually perfused microvessels, which measures the volume of water flux across the microvessel wall. Details have been described previously (Yuan et al. 2012, Yuan et al. 2014).

Staining for metachromatic myosin ATPase

To identify skeletal muscle fiber type, a metachromatic myosin ATPase stain was performed using a modified protocol (Ogilvie & Feeback 1990). Sections were pre-incubated in an acidic buffer (pH=4.25) to differentially inhibit myosin ATPase within the different fiber types. In this protocol, type I fibers appear dark blue, type IIa appear light blue and type IIb and IIx are not apparent from each other and are classified as IIb/x. These fibers appear almost white and are the largest. Images were acquired with a Nikon Eclipse 90i microscope and Q-imaging MicroPublisher with Q-Capture software at 10× magnification.

Immunohistochemistry of Ad and dystrophin in skeletal muscle

Tibialis anterior (TA) from control and CORT-treated rats were cryostat sectioned (10µm thick) for the analysis of muscle Ad content. Sections were stained as previously described (Krause et al. 2008). Quantification was performed using Zen 2.0 software. The total Ad and dystrophin signals were determined by the sum of red/green signal intensity obtained and arbitrary values in the field of view. Diagram view intensity was recorded by the software in the form of histograms. Intracellular quantification was done on Ad images (without dystrophin), images were changed to 8 bits on Image, and the arbitrary intensity was calculated as mean intensity per area.

Western blot analysis

Control and DEX-treated HUVECs, and L6 or H9C2 cells treated with HUVEC-conditioned medium and soleus skeletal muscle were lysed in sample buffer (80 mM Tris–HCl (pH 6.8), 2% (w/v) SDS, 20% glycerol, 3.3% (v/v) β-mercaptoethanol and 0.01% (w/v) bromophenol blue) containing protease and phosphatase inhibitors (3 mM EDTA, 100 µM E64, 1 mM Na3VO4, 10 µM leupeptin, 1 µM pepstatin A, 1 µM okadaic acid and 200 µM PMSF). Apical and basolateral HUVEC-conditioned media collected from Ad flux experiments were concentrated with Amicon Ultra-4 Centrifugal Filter Units with Ultracel-10K membranes (EMD Millipore) and subjected to non-denaturing, non-reducing conditions to allow the analysis of the different forms of Ad (HMW >250 kDa, MMW ~180 kDa, and LMW ~90 kDa). Primary antibodies are specific for the following proteins; T-cadherin (1:1000, R&D Systems), occludin (OCLN, 1:3000), tricellulin (TRIC, 1:3000), claudin-7 (CLDN-7, 1:500), CLDN-10 (1:800), CLDN-11 (1:1000), phospho-AMPKα (Thr172) (1:1000), phospho-p38 MAPK (pT180/pY182) (1:1000), Ad (1:1000) and β-actin (1:1000). OCLN, TRIC, CLDN-7, CLDN-10 and phospho-p38 MAPK (pT180/pY182) antibodies were obtained from Life Technologies, CLDN-11 and Ad antibodies were purchased from EMD Millipore and Signalway Antibody, respectively, and phospho-AMPKα (Thr172) and β-actin antibodies were obtained from Cell Signaling Technology (New England Biolabs Ltd., Whitby, ON, Canada). Protein was detected using enhanced chemiluminescence (Bio-Rad) and quantification by densitometry using ImageJ analysis software. TJ protein expression was normalized to β-actin, Tubulin protein abundance.

Statistical analysis

All data are expressed as mean values ± S.E.M. A one-way analysis of variance (ANOVA) followed by a
Student–Newman–Keuls test was used to determine significant differences \((P \leq 0.05)\) between groups. When appropriate, a Student’s \(t\)-test was also used. All statistical analyses were conducted using Prism 5, Excel SigmaStat 3.5 software.

Results

Dexamethasone induces endothelial tightening and inhibits Ad movement across endothelial cell monolayers

We first investigated the effect of dexamethasone (DEX), a synthetic glucocorticoid, on tightness of an endothelial monolayer of HUVECs. Addition of DEX to culture media significantly elevated TEER (Fig. 1A) and correspondingly reduced the endothelial permeability of the paracellular transport marker [\(^{3}\)H]PEG-4000 (Fig. 1B). Similar trends regarding permeability were observed in microvessels of DEX-treated rats. DEX treatment \((n=4)\) did not cause a significant reduction in baseline Lp compared to normal control group \((n=6)\), but lowered the mean value from \(1.5 \pm 0.1\) to \(1.1 \pm 0.2\) \((\times10^{-7}\text{cm/s/cm H}_2\text{O})\). When each vessel was exposed to platelet-activating factor (PAF, \(10\text{nM}\)) that is known to cause transient increases in Lp (Zhou & He 2011), microvessels in DEX-treated rats showed significantly attenuated Lp response. The mean peak Lp value was reduced from \(11.1 \pm 1.8\) \((\times10^{-7}\text{cm/s/cm H}_2\text{O})\) (normal control) to \(6.0 \pm 0.4\) \((\times10^{-7}\text{cm/s/cm H}_2\text{O})\), (Fig. 1C).

Figure 1

Effects of DEX on permeability. HUVECs (Human Umbilical Vein Endothelial Cell) were seeded onto permeable polyethylene terephthalate (PET) filters and treated with or without \(1\mu\text{M}\) of DEX every other day in both top and bottom of compartments. Tightness of the monolayer was measured on the 5th day of DEX treatment. (A) Transendothelial Electrical Resistance (TEER). (B) [\(^{3}\)H]PEG-4000 permeability across HUVEC monolayer. (C) Measurements of hydraulic conductivity (Lp) in individually perfused mesenteric venules from normal \((n=6)\) and Dex-treated \((n=4)\) rats. DEX treatment significantly attenuated the Lp responses to PAF that was known to cause transient increases in Lp. (D, E and F) 10 µg of full-length Ad was added onto the apical side. After 24h, the medium on basolateral was collected. (D) Total Ad amount was quantified using ELISA. (E) The collected basolateral medium was concentrated and separated by PAGE. 3 forms of Ad are labeled as LMW (~90 kDa), MMW (~180 kDa) and HMW (>250 kDa). (F) Representative Western blot for full-length Ad flux across control and Dex-treated monolayers. Data are expressed as mean values \(\pm\) s.e.m. \((n=4–8)\). *Significant difference \((P \leq 0.05)\) from control (Con) group.
We then assessed flux of Ad from the apical to basolateral side of HUVEC monolayer and found a reduced total amount of Ad in basolateral media after DEX treatment (Fig. 1D, E and F). When monitoring absolute flux rates in control cells, Ad flux rate was $4.4 \pm 0.12 \text{ cm/s} \times 10^{-9}$, which significantly decreased after DEX treatment to $3.2 \pm 0.30 \text{ cm/s} \times 10^{-9}$ (Fig. 1D). Following a 24-h flux period, Ad levels detected in basolateral media were $64.8 \pm 5.7 \text{ ng/mL}$. Using Western blotting to examine various oligomeric forms of Ad LMW ($\sim 90 \text{kDa}$), MMW ($\sim 180 \text{kDa}$) and HMW ($\sim 250 \text{kDa}$), we found that flux of all forms was reduced by DEX (Fig. 1E and F). Additionally, the functional activity of Ad appearing in basolateral media was confirmed by using this media to treat L6 skeletal muscle cells and H9C2 cells derived from rat heart ventricle. In both cell types, the media increased AMPK phosphorylation (Supplementary Fig. 1A and B, see section on supplementary data given at the end of this article).

**Figure 2**

Effect of DEX on tight junction components. (A) mRNA abundance by qRT-PCR analysis. HUVECs grown to confluence on permeable PET inserts. Total RNA was isolated from control cells on the 5th day. Transcript abundance was normalized to GAPDH and each gene examined was expressed relative to OCLN transcript abundance. (B) TJ transcript levels in DEX-treated cells were normalized to GAPDH, and expressed relative to the control group (blue – increasing compared to control; green – decreasing compared to control). Data are expressed as mean values $\pm$ s.e.m. ($n=3–8$). (C) Protein abundance in HUVECs grown on cell culture inserts. Protein abundance were normalized to $\beta$-ACTIN, and expressed relative to the control group. (D) Representative Western blots of CLDN-1, -7, -10, -11, -15, TRIC, OCLN, ZO-1. Data are expressed as mean values $\pm$ s.e.m. ($n=3–8$). *Indicates significant difference ($P \leq 0.05$) from control (Con) group.

Dexamethasone treatment alters transcript and protein abundance of select TJ proteins in HUVEC monolayers

A tissue expression profile of transcripts encoding 26 TJ proteins in HUVECs revealed the presence of 15 (Fig. 2A). The most abundant transcript was found to be *Cldn-11*, while *Cldn-7*, *Cldn-12* and *ZO-1* exhibited relatively high abundance and *OCLN*, *TRIC*, *CLDN-10* and *CLDN-15* exhibited moderate levels of abundance (Fig. 2A). Transcripts not detected in HUVECs included *CLDN-3*, -4, -5, -8, -9, -16, -17, -18, -19, -23 and -25 (Fig. 2A and Supplementary Fig. 1C). Human kidney cDNA was used as a positive control for transcripts that were not detected in HUVECs (Supplementary Fig. 1C). To explore the response of TJ proteins to DEX treatment, we first compared mRNA abundance of expressed target genes in HUVECs. DEX increased *CLDN-6* mRNA abundance while *CLDN-2*, -20, -22, -24 and *ZO-1* mRNA showed significant decreases (Fig. 2B). DEX treatment had no significant effect on mRNA encoding *OCLN*, *TRIC*, *CLDN-1*, -7, -10, -11, -12...
and -15 (Fig. 2B). Following DEX treatment, the protein abundance of CLDN-1, -7, -11 and ZO-1 was examined and found to be significantly upregulated following DEX treatment when compared to the control group (Fig. 2C and D). On the other hand, CLDN-10 protein levels were significantly decreased when compared with the expression in control conditions (Fig. 2C and D). In order to validate the functional significance of Dex-induced changes in the expression of tight junction proteins, we used shRNA to target claudin-7 and this effectively reduced its expression by 71% on average (Fig. 3A). Furthermore, HUVEC with reduced levels of claudin-7 showed reduced TEER and a small but significant increase in flux of adiponectin from apical to basolateral side (Fig. 3B, C and D).

Examination of changes in transcellular endothelial flux

The possible contribution of transcellular receptor-mediated Ad movement across HUVEC monolayers was then investigated by analysis of expression levels of three identified Ad receptors. Intracellular Ad content in these cells was detected, although at low level, and expression levels did not change significantly with DEX treatment (Fig. 4A). However, DEX significantly increased T-cadherin protein abundance (Fig. 4B), but had no effect on protein abundance of AdipoR1 and AdipoR2 (Fig. 4C).

Skeletal muscle Ad content in a rat model of exogenous glucocorticoid-induced diabetes

We then examined whether the increased endothelial cell barrier tightness observed after DEX treatment would be paralleled in a diabetic rodent model of chronic glucocorticoid exposure. As expected based on previously published work (D’Souza et al. 2012, Shikatani et al. 2012, Shpilberg et al. 2012), two weeks of exogenous corticosterone (CORT) treatment resulted in severe fasting hyperinsulinemia and impaired glucose tolerance (Supplementary Fig. 2A). In addition, CORT treatment caused mild/moderate elevations in fasted blood glucose concentrations (5.12 ± 0.2–8.3 ± 1.88 mM, Supplementary Fig. 2B) despite the significantly increased fasting insulin concentrations (0.76 ± 0.25–4.68 ± 0.72 ng/mL, Supplementary Fig. 2C). CORT treatment also caused a change in skeletal muscle fiber type composition, a switch from predominantly slow- to fast-twitch skeletal
Figure 4
Expression of Ad and its receptors in HUVEC. (A) Ad expression in HUVECs treated with DEX after 5 days. (B) T-CADHERIN expression in HUVECs with DEX treatment. (C) ADIPO-R1/R2 expression in HUVECs. Data are expressed as mean values ± s.e.m. (n = 3–6). * Indicates significant difference (P ≤ 0.05) from control (Con) group.

Figure 5
Ad level in CORT-treated animals. (A) Using ELISA, circulating Ad was calculated in 1-week treated rat serum. (B) Ad mRNA expression after 14 days of CORT. (C and D) Representative Western blotting and quantitation of reduced Ad (~30 kDa) in soleus skeletal muscle. (E) Immunohistochemical detection of dystropin (green), Ad (red) in skeletal muscle isolated from rats after 2 weeks of CORT treatment, together with quantitation in F. (G) Quantification of changes in intracellular Ad levels and (H) cell number. Quantification of Ad shown as the intensity expressed per cell in arbitrary units and is expressed as mean values ± s.e.m. (n = 3–5). * Indicates significant difference (P ≤ 0.05) from control (Con) group.
muscle fibers, within the tibialis anterior muscle (Supplementary Fig. 2D).

To explore whether CORT treatment affects circulating Ad levels, we measured plasma Ad levels in these animals before CORT pellet implantation and at 7 days post pellet implantation, at 08:00 h. Circulating Ad levels were unaffected by CORT treatment (Fig. 5A). Interestingly, there was an apparent elevation in skeletal muscle Ad mRNA levels (Fig. 5B), yet Ad protein content was significantly reduced (Fig. 5C and D). Upon immunohistochemical analyses, we also observed that the total amount of Ad was decreased in skeletal muscle from the CORT-treated rats vs control rats (Fig. 5E, F, G and H). Dystrophin was used to assess the structural integrity of the skeletal muscle and was unaffected by CORT treatment. Representative images are shown (Fig. 5E) with quantification of the total and intracellular Ad signal (Fig. 5G and H). Since CORT treatment is known to preferentially target fast-twitch skeletal muscle (Beaudry et al. 2015), representative images accordingly depict smaller IIb/x fiber area (Fig. 4D) within the CORT-treated rats. CORT treatment was also found to cause a significant reduction in individual myocyte size (Fig. 5F).

AdipoR abundance in a rat model of exogenous glucocorticoid-induced diabetes

Both Ad receptor isoforms (AdipoR1 and AdipoR2) genes were expressed in rat soleus skeletal muscle and although an apparent increase in AdipoR1 mRNA abundance was seen in the diabetic rat model, neither was significantly altered (Fig. 6A and B). However, a significantly increased level of ADIPO-R1 protein (approximately 3.4 fold compared to the control) was seen (Fig. 6F). There were no changes in ADIPO-R2 nor in T-Cadherin protein levels (Fig. 6E and G).

Figure 6
Ad receptor expression in skeletal muscle. Rats were treated with CORT for 2 weeks. (A and B) mRNA expression of Ad and its receptors after 14 days of CORT. Data are expressed as mean values ± S.E.M. (n=4-5). (C and D) mRNA profile of tight junction in soleus skeletal muscle isolated from 2 weeks CORT-treated rats. mRNA abundance by qRT-PCR analysis. Transcript abundance was normalized to GAPDH mRNA abundance, and mRNA abundance for each gene examined was expressed relative to control group transcript abundance. Control group gene transcript was normalized to 1. (C) mRNA profile of TJ that is increased after 2-week CORT treatment compared to control (blue – CORT-treated, red – Control. (D) TJ genes that are decreased after 2 weeks of CORT treatment. (E, F and G) Protein expression in soleus. (E) T-CADHERIN. (F) Ad receptor 1. (G) Ad receptor 2. Data are expressed as mean values ± S.E.M. (n=3). *Indicates significant difference (P≤0.05) from control group.
CORT treatment altered tight junction genes in rat soleus skeletal muscle after 2 weeks

We then measured changes in transcript abundance of tight junctions components, Cldn-1, -2, -3, -4, -5, -6, -7, -9, -10, -11, -12, -24, -14, -15, -19, -20, -22, -23 and Ocln, Tricand ZO-1 were found to have no significant changes within diabetic rat skeletal muscle (Fig. 6C), whereas Cldn-5, -10, -11, -22 significantly decreased (Fig. 6D).

Discussion

Glucocorticoids are potential mediators of endothelium permeability. Our study was designed investigate its influence on endothelium permeability and consequently the changes in Ad movement across the endothelium barrier and the underlying mechanism. More recently, a similar proposed mechanism for regulation of Ad action was suggested both by us and others (Rutkowski et al. 2014, Yoon et al. 2014). To the best of our knowledge, the regulation of this process by glucocorticoids had not been studied before. Our vitro model using DEX-treated HUVEC and CORT-treated rats to integrate the established observations that glucocorticoids can restrict paracellular transport across various endothelia (Keaney & Campbell 2015, Rao et al. 2015, Rochfort & Cummins 2015) with the fact that glucocorticoids, commonly prescribed medications, have numerous side effects, including insulin resistance and diabetes (Beaudry et al. 2015). Furthermore, we examined whether the emerging phenomenon that transendothelial movement of Ad may regulate the anti-diabetic effects of this hormone and whether this was regulated by glucocorticoids (Rutkowski et al. 2014, Yoon et al. 2014). Specifically, our approach involved the use of endothelial cell monolayers and individually perfused intact microvessels to examine whether glucocorticoid-altered Ad flux was through reduced microvessel permeability. We also used a rat model of diabetes induced by exogenous glucocorticoid treatment to determine changes in Ad content in muscle as well as peripheral insulin sensitivity.

As indicated in the introduction, strong rationale for this work comes from previous studies with other circulating hormones, most notably insulin. Concentrations of insulin at the cell surface have been shown to be very different from those observed in plasma in microdialysis experiments (Sjostrand et al. 1999, Herkner et al. 2003), direct interstitial sampling (Bodenlenz et al. 2005) and lymph measurements (Yang et al. 1994, Chiu et al. 2008).

It was noted that insulin-mediated glucose uptake lagged behind the increase in plasma insulin (Freidenberg et al. 1994), whereas in cultured skeletal muscle cells, insulin-mediated glucose uptake occurs within 10 min (Somwar et al. 2001). The time delay seen in vivo (Freidenberg et al. 1994) reflects a delay in insulin access to the myocyte which is mediated in part via altered paracellular or transcellular endothelial transport. Thus, modification of access to skeletal muscle can have major effects on insulin action and metabolism, suggesting that reaching the interstitial space is the limiting factor for insulin-mediated glucose uptake (Kolka & Bergman 2012). Indeed, delivery of insulin to the interstitial space has been shown to be altered by diet (Kubota et al. 2011).

We confirmed the ability of the synthetic glucocorticoid DEX to alter endothelial transport properties, in this case of HUVEC monolayers, as indicated by changes in TEER and PEG-4000. Similar effects were observed in DEX-treated rats, where we saw a significant reduction of permeability in rat mesenteric venules. We then showed that DEX reduced Ad flux across cultured endothelial monolayers by ELISA detection of total Ad content. Western blotting of Ad isoforms indicated that all three oligomeric forms of Ad (trimer, hexamer and oligomer) were reduced in basolateral media from DEX-treated cells, and although the magnitude of change was more evident in the case of LMW adiponectin, all isoforms were significantly altered and we do not believe these data infer a preferential restriction of LMW flux. This demonstration of restricted flux is important to establish from several perspectives. First, many studies have suggested that oligomeric high-molecular-weight complexes of Ad are most tightly correlated with insulin resistance (Pajvani et al. 2004, Liu et al. 2007). Second, the concept that endothelial transport regulated Ad action was also proposed by a recent study, which estimated the size of different Ad forms by calculating a Stokes radius (Rutkowski et al. 2014). The Stokes radii were 3.96 nm for trimeric Ad, 6.01 nm for hexameric Ad and 10.1 nm for various HMW oligomeric forms (Rutkowski et al. 2014), and these sizes are likely to be in the range that can be physically obstructed or facilitated by changes in endothelial cell tight junction size. Indeed, it was concluded that Ad bioavailability and action in target cells were attenuated under stressed conditions due to reduced transendothelial transport (Rutkowski et al. 2014). We concur that the regulation of Ad flux across endothelium is particularly relevant since the target tissues where Ad mediates its physiological effects have a
wide range of endothelial permeability. Liver, for example, has highly fenestrated endothelium that may permit the passage of HMW Ad, which has potent effects on hepatic metabolism. In contrast, the central effects of HMW Ad may be limited by its transport across the comparatively tighter blood–brain barrier (Yoon et al. 2014).

The well-established effect of glucocorticoids to restrict endothelial transport has been proposed to be mediated via regulation of TJ and adherents junction (AJ) proteins (Felinski & Antonetti 2005, Blecharz et al. 2008). Strands of transmembrane and cytosolic proteins form TJ and AJ complexes that regulate permeability between endothelial cells (Gunzel & Fromm 2012). Functional characteristics of the vetebrate TJ complex are dependent on the variable assemblage of TJ proteins such as occludin (OCLN), tricellulin (TRIC) and, in particular, claudins (CLDNs), which directly establish the TJ barrier and form the backbone of TJ strands, while cytosolic ZO-1 and other cortical TJ proteins provide structural support to the TJ complex (Gunzel & Fromm 2012). The CLDN superfamily consists of at least 27 isoforms in mammals and the incorporation of specific CLDN isoforms in TJs can modulate TJ barrier function by making the paracellular pathway tighter or leakier (Gunzel & Yu 2013). The main observations in our study were increased CLDN-7 and decreased CLDN-10 protein abundance in HUVEC in response to DEX, and these changes may underlie the functional properties of paracellular transport limiting Ad flux. Little is known about CLDN-7, although CLDN-7 knockout is lethal in murine models, and it seems that CLDN-7 most likely facilitates anion movement across vertebrate epithelia. CLDN-7 was previously found to form a complex with the epithelial cell adhesion molecule (EpCAM), which enhanced cell–cell interaction (Krug et al. 2012, Verma & Molitoris 2015). We suggested that the functional role of CLDN-7 in our model is tightening of the endothelium in association with an increase in abundance, and that this may help to explain, in part, the restricted movement of Ad in DEX-treated HUVEC as well CORT-treated rats. Further supporting this idea, a previous study has found that CLDN-7 (−/−) can cause colonic inflammation and enhance the paracellular flux of small organic solutes (Tanaka et al. 2015), as well as observations that CLDN-7 (−/−) results in the presence of intercellular gaps below TJs and cell matrix loosening (Ding et al. 2012). Thus, we used shRNA to target claudin-7 in HUVEC and observed that this caused a decrease in TEER and increase in adiponectin flux across monolayers, further indicating an important mechanistic role for Dex-mediated changes in claudin-7 expression. Interestingly, another group found that NLRP3 inflammasome promoted endothelial disruption via production of HMGB1 to disrupt the junctions and increased paracellular permeability (Chen et al. 2015). Finally, Tatum and cowokers (Tatum et al. 2010) reported that urine Na(+), Cl(−) and K(+) were significantly increased in CLDN-7(−/−) mice compared with those of CLDN-7(+/+) mice. Taken together, the studies outlined above and our data indicate an important functional consequence for CLDN-7 reduction and compromised epithelial permeability as the result of tight junction disruption, and this supports the view that increased CLDN-7 abundance, as seen in these experiments, may contribute to endothelial tightening and reduced Ad flux.

In contrast, CLDN-10 isoforms in vertebrate epithelia have been described to impart both charge- and size-selective properties to the paracellular pathway. Previous studies investigated the role of CLDN-10-deficient mice using Cre-Lox and found that serum phosphate concentration was 28% higher and serum Mg²⁺ concentration was almost twofold higher in cKO mice compared with controls. However, the same study also found that CLDN-10 transports molecules in a charged selective manner (Breiderhoff et al. 2012). To the best of our knowledge, Ad is uncharged. Therefore, the transport of Ad is less likely to be affected by CLDN-10. Nevertheless, it would be very interesting to explore whether the consistent decrease in CLDN-10 observed in this study has a functional role in the modulation of Ad transport across the endothelium barrier.

In the glucocorticoid-induced diabetic rodent model used here, a decrease in CLDN-10 mRNA expression in skeletal muscle was also observed. Although changes in expression profiles of other tight junction proteins do not entirely match the changes in HUVEC treated directly with DEX, this is not entirely surprising since there are multiple factors impinging upon tight junction protein expression in skeletal muscle tissue in vivo.

We believe that reduced paracellular transport is the main mechanism of reduced Ad flux observed, yet we also tested possible indicators of altered transendothelial flux (Yoon et al. 2014). In DEX-treated endothelial cells, there was no major change in ADIPO-R1 or ADIPO-R2 mRNA and protein expression, although in skeletal muscle homogenates, ADIPO-R1 protein expression levels increased significantly in CORT-treated animals. This may reflect a compensatory mechanism to reduced Ad availability in order to increase sensitivity to available
Ad. We also observed that DEX increased expression of T-cadherin in HUVEC. T-cadherin has been identified as a non-functional receptor for Ad (Hug et al. 2004). This is in agreement with a previous study showing that DEX enhanced T-cadherin expression in human osteosarcoma cells (Bromhead et al. 2006). One possible interpretation of our finding is that binding to endothelial T-cadherin may trap Ad in the vasculature, as has recently been proposed (Matsuda et al. 2015).

We also investigated potential alterations in endothelial transport of Ad in a rodent model of glucocorticoid-induced diabetes (Shpilberg et al. 2012). In these rats, we found normal circulating Ad levels but significantly reduced total Ad protein content within skeletal muscle without an accompanying decrease in muscle Ad gene expression. This suggests that less flux of Ad from circulation could be a contributory mechanism. Indeed, upon immunohistochemical analysis, we found reduced Ad content in the interstitial space. Although not a direct comparison to the in vitro studies we used here, it suggests that skeletal muscle Ad availability, and thus action, may be limited in this animal model possibly contributing to its diabetic phenotype (Shpilberg et al. 2012, Beaudry et al. 2013, 2014, 2015, Yoon et al. 2014).

In conclusion, our study indicates that glucocorticoid-mediated tightening can reduce flux of Ad across endothelial monolayers, and that this may be due to alterations in the expression profile of tight junction proteins. Furthermore, in a rat model of diabetes induced by exogenous glucocorticoids, we observed reduced interstitial and intracellular levels of Ad in skeletal muscle. Thus, we propose that reduced Ad action in target tissues, as a consequence of reduced endothelial flux from circulation to interstitial space, may contribute to the diabetic phenotype occurring after glucocorticoid treatment. Since glucocorticoids are one of the most commonly prescribed medications, our discovery of reduced Ad transport in response to glucocorticoids is a particularly important and novel finding with potentially far-reaching consequences.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/JOE-16-0363.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was initially funded by an operating grant to G S from Canadian Institutes of Health Research and then by Natural Science and Engineering Research Council of Canada Discovery Grants to G S, S P K and M C R. P H was funded by the National Institutes of Health (US) HL58237 and DK097391. G S also acknowledges Career Investigator support from Heart & Stroke Foundation of Ontario.

Acknowledgements
We also greatly appreciate the contribution of Dr Tara Haas via advice on quantifications of skeletal muscle tissue immunostaining.

References


Received in final form 26 April 2017
Accepted 10 May 2017